GLP-1, SGLT2 medications may lower stroke survivor’s risk of …
3 days ago — The SGLT2 medications canagliflozin, dapagliflozin, empagliflozin and ertugliflozin are approved by the FDA for the treatment of Type 2 diabetes. To analyze the impact of these …
GLP-1 and SGLT2 inhibitors show promise in ... - News-Medical.net
2 days ago — GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart …
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent
19 hours ago — (HealthDay News) — For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 …
GLP-1, SGLT2 medications may lower stroke sur | EurekAlert!
3 days ago — GLP-1, SGLT2 medications may lower stroke survivor’s risk of future heart attack, stroke American Heart Association Scientific Sessions 2024, Abstract 4148007
SGLT-2 inhibitors for the prevention of recurrent nephrolithiasis
Nov 7, 2024 — Their findings are consistent with another large study of claims data from the US, showing that among people with type 2 diabetes, those taking SGLT-2 inhibitors had a …
Effects of sodium-glucose cotransporter-2 inhibitor on atrial
2 days ago — Prior research has demonstrated an association between sodium-glucose cotransporter 2 (SGLT2) inhibitor and a reduced incidence of atrial fibrillation (AF). Given the …
FDA approves first SGLT1/SGLT2 inhibitor for heart failure
Jun 29, 2023 — Inpefa is the first SGLT inhibitor that works in both the kidneys and the small intestine to treat heart failure. It reduces cardiovascular deaths and hospitalizations by 33% …
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults …
Oct 1, 2024 — Current practice Few therapies slow kidney disease progression and improve long term prognosis for adults living with CKD. SGLT-2 inhibitors have demonstrated …
FDA Update: Sotagliflozin Approved For Broad HF Treatment
Jun 5, 2023 — Sotagliflozin (Inpefa) is the first dual SGLT1 and SGLT2 inhibitor for heart failure (HF) with or without type 2 diabetes. The FDA approved it based on phase 3 trials that showed …
Applications of SGLT2 inhibitors beyond glycaemic control
Apr 26, 2024 — SGLT2 inhibitors reduce the risk of cardiovascular death and heart failure hospitalization among people with type 2 diabetes mellitus and have beneficial effects on key …